TransMedics Corp is a medical technology company specializing in systems to preserve, monitor, and transport donor organs such as hearts, lungs, and livers. Its Organ Care System (OCS) enables longer preservation of organs outside the body, significantly improving transplant success rates. Over the past five years, TMDX’s stock has surged 300%, fueled by accelerating adoption of its OCS program. Quarterly revenues have risen from $42 million to $109 million in just seven quarters.
However, Q3 2024 marked TMDX's first negative quarterly revenue growth since 2022. Management attributed this to temporary factors, including maintenance on its organ transport fleet, which reduced the number of flights undertaken and caused revenue declines. The maintenance also increased costs as TMDX relied on third-party planes for some trips, further compressing gross margins. Importantly, management indicated in the earnings call that these challenges should normalize going forward, setting the stage for material gross margin expansion in subsequent quarters. Despite this, the stock has dropped ~50% from its all-time highs (ATH), and as of 28th November 2024, almost 30% of the float has been shorted. This presentsa compelling buying opportunity to the contrarian, and intelligen investor.
We are long TMDX for the following reasons:
Investment Thesis:
1. Strong Operational Recovery Points to Record Q4 Performance
In Q3 2024, TMDX reported a fleet of 18 planes for organ transport. Using FAA data and jetspy.com, we tracked monthly flight activity and found the fleet's operations have significantly rebounded in Q4:
2024 Flights by Quarter
Q1 (14 planes): 661 flights
Q2 (17 planes): 1,474 flights
Q3 (18 planes): 1,376 flights
Q4 (as of Nov 28, 18 planes): 1,012 flights
The reduced number of flights in Q3 stemmed from fleet maintenance, which limited operational capacity and necessitated the use of costly third-party planes. These factors weighed on gross margins and overall profitability. However, with the fleet performing better, TMDX performed 17.4 flights per day in Q4 (as of Nov 28), projecting 1,570 flights for the quarter—a record high. Historically, December sees elevated transplant activity due to alcohol-related accidents, suggesting an even stronger Q4 finish.
Despite low transplant volumes nationally, TMDX’s rising flight numbers signal growing market share and adoption of its OCS technology. The normalization of fleet operations should also lead to lower costs and margin recovery in Q4 and beyond, making us confident in robust earnings growth and outperformance in upcoming reports.
2. Resilience Amid Temporary National Headwinds, Setting the Stage for Explosive Growth
National transplant volumes have declined in Q3 and early Q4 2024 due to cyclical factors. Data from the Organ Procurement and Transplantation Network (OPTN) illustrates this trend:
2024 Transplants per Day
Q1: 31.64
Q2: 32.98
Q3: 31.4
Q4 (as of Nov 28): 30.07
Such declines are typical during this time of year. Transplant volumes historically peak in December and Q1, driven by seasonal factors like increased alcohol-related accidents. These cyclical lows have weighed on TMDX’s Q3 performance and investor sentiment. However, this temporary dip in transplant activity obscures a critical trend: TMDX has significantly expanded its market share and captured more customers, even during a period of reduced demand.
Market Share Gains Amidst Headwinds
TMDX’s operational resilience and aggressive market expansion are evident in its growing flight numbers. While overall transplant activity in the U.S. has hit yearly lows, TMDX’s fleet activity is on track to achieve record highs in Q4 2024. This signals that hospitals are increasingly adopting TMDX’s Organ Care System (OCS) and shifting transplant orders to the company.
This means that TMDX has signed up new customers during this period, leveraging its technological edge and superior outcomes. These new customers, combined with existing ones, are likely to significantly increase transplant volumes as overall demand normalizes. This sets the stage for a substantial boost to TMDX's revenue in 2025 when seasonal factors drive transplant volumes higher.
Revenue Explosion in 2025 and Beyond
More Transplant Orders Despite Lower Volumes: TMDX has demonstrated its ability to grow transplant orders even in a low-demand environment, thanks to its aggressive market share expansion. This growth is particularly significant because new and existing customers will perform more transplants in 2025 when national transplant volumes rebound due to seasonal factors. As transplant volumes rise, these orders will translate directly into a significant surge in earnings.
Seasonal Tailwinds: December and Q1 have historically been the busiest periods for organ transplants. With TMDX’s fleet operating at peak capacity and an expanded customer base, the company is uniquely positioned to capitalize on this surge in demand.
Widening Adoption Curve: Hospitals that adopt the OCS system during periods of operational stress are unlikely to revert to traditional methods, ensuring sustained growth in transplant orders as demand normalizes.
Mispricing of Growth Potential
Investors have failed to appreciate the strategic importance of TMDX’s market share gains. The company is being punished for temporary cyclical factors, even as it lays the groundwork for outsized growth. The increase in transplant orders during a historically low-demand period suggests that TMDX is becoming a critical player in the organ transplant ecosystem.
As transplant volumes return to normalized levels, TMDX’s outsized market share will magnify revenue growth. This misalignment between the company’s operational performance and market sentiment creates a unique opportunity for investors to capitalize on a temporary inefficiency.
As a side note, the unravelling of the short interest, which we think may induce some buying pressure from short-covering, can be a reason for future short term price appreciation as well. This, coupled with the end of tax-loss selling in 2025, serves as some great ‘technical’ catalysts.
Valuation
TMDX is currently valued at 7.2x trailing twelve-month sales, which reflects the market's acknowledgment of its high growth potential and dominant position in the organ transplant ecosystem. While this multiple is higher than traditional medtech averages (typically in the 3–5x range), several factors make it attractive:
High Growth Rate Justifies Premium:
TMDX has grown its quarterly revenue from $42 million to $109 million in seven quarters, an annualized growth rate far outpacing traditional medtech firms. This growth trajectory supports a higher sales multiple, especially given its market dominance in the OCS space. TMDX has a huge growth runway even if we exclude all the analysis done in this writeup. Apart from the Liver segment(accounting for about 70% of revenyes), TMDX is on track to launch its OCS Lung clinical program to drive adoption, and is investing further capital to expand market share on the heart and lung segment as well!
Market Leadership with Minimal Competition:
TMDX operates in a niche market with limited competition, providing it with a significant moat due to it being the only FDA-approved solution. The Organ Care System (OCS) is a revolutionary technology that hospitals are increasingly adopting, as evidenced by rising flight activity even in a low-demand environment. This unique position reduces the risk of immediate margin compression or disruption, making the premium valuation more defensible. Since TMDX’s solution is the only FDA-approved product, TMDX can easily expand its solutions to multiple transplant-able organs and gain market share. According to investor presentations, this is its primary goal- to expand utilisation and adoption via its clinical trials for the lung and heart segment. In the Q3 2024 Earnings call, the CEO of TMDX said ‘our clinical programs that are designed for next year is to expand our reach even further in lung and heart and tackle areas that we have not tackled yet’.
Explosive Revenue Potential Ahead:
The current multiple does not fully account for the substantial revenue growth expected in 2025. With TMDX signing up new customers, increasing transplant orders, and benefiting from seasonal tailwinds, its revenues are poised for an outsized surge when transplant volumes normalize. This forward-looking growth could compress the sales multiple significantly in the coming quarters, offering upside for investors.
Gross Margin Expansion and Operating Leverage:
The normalization of fleet maintenance costs, reduced reliance on third-party planes, and rising volumes will drive significant gross margin expansion. As operating leverage kicks in, profitability will scale faster than revenue, further justifying a higher multiple.
Peer comparison
While TMDX’s 7.2x sales valuation is higher than the medtech industry average, it remains reasonable compared to high-growth, innovative peers in adjacent healthcare technology spaces. Many growth-focused medtech or biotech firms with disruptive technologies trade at 10–15x sales, particularly when they are at an inflection point for profitability. For instance:
Intuitive Surgical (ISRG), a mature leader in robotic-assisted surgery, which is almost at the end of its growth curve, trades at a lofty 24.5x sales
Xvivo Perfusion(STO: XVIVO), A peer of TMDX operating in the organ preservation industry, trades at about 19x sales.
Given TMDX’s unique position, early-stage growth curve, and limited competition, its 7.2x multiple appears relatively conservative, especially as revenues are set to accelerate.
Risks:
Fleet Maintenance: Persistent fleet issues could increase costs.
Prolonged Transplant Volume Decline: A delayed recovery in transplant activity would hinder growth.
Competition: Although minimal now, new entrants could erode market share.
Catalysts:
Earnings Confirmation: Future reports should validate that growth remains intact.
Normalization of Transplant Volumes: Seasonal recovery in 2025 will amplify revenue.
End of Tax-Loss Selling: This temporary pressure should subside post-Q4.
Conclusion:
TMDX represents a compelling opportunity in the medtech space. Despite temporary setbacks, the company continues to expand its market share and demonstrate resilience during a cyclical downturn. With strong tailwinds on the horizon—normalizing transplant volumes, a robust flight recovery, and a misunderstood Q3—TMDX is well-positioned for explosive growth in 2025. At current valuations, it is a screaming buy for long-term investors.
The GOAT has returned
What do you think of the (342 pages!) short thesis by Scorpion Capital? I would personally not touch any company before disproving all bear arguments. Either way, this company is too complicated for me anyways. Cheers